ArticleJournal of neuromuscular diseases2026
Change in respiratory outcomes in adults with Duchenne muscular dystrophy in the era of corticosteroids.
Article in Journal of neuromuscular diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Congenital Clubfoot as an Early Manifestation of Duchenne Muscular Dystrophy?Muscles (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn patients with Duchenne muscular dystrophy (DMD) the effect of continued corticosteroid (CS) use into adulthood on respiratory function remains unclear. We studied if prolongation of CS into adulthood is beneficial for forced vital capacity (FVC), age at start of non-invasive ventilation (NIV), and age at start of continuous (24/24 h) ventilation.
methodsIn this retrospective study, adult (≥18 years) DMD patients were stratified into 20 'CS-naïve' patients (never used CS or only as a child during <1 year) and 37 'continued CS' patients (continued CS until age of 18 years or older).
results'Continued CS' patients showed at 18 years a higher FVC%pred (50.3, SD:16.4) compared to 'CS-naïve' patients (36.9, SD:13.8) (p = 0.007). Patients continuing CS beyond the age of 18 demonstrated a slower annual decline in FVC%pred of 2.9% (SE:0.5) in comparison to 3.8% (SE:0.4) in the 'CS-naïve' group, and the difference in relative annual decline in FVC%pred was significant (p = 0.012). The annual decline in FVC in absolute value in patients continuing CS was 102 ml (SE:28) slower in comparison to 'CS-naïve' patients (p < 0.001). Moreover, there was a delay in age at initiation of NIV: mean age at start of NIV was 28.3 (95%CI: 25.4-31.2) in 'continued CS' in comparison to 20.3 (95%CI: 19.0-21.6) in 'CS-naïve' patients (p < 0.001), and at start of continuous NIV 33.3 (95%CI: 31.5-35.2) in comparison to 26.0 (95%CI: 24.7-27.2) years (p < 0.001).
conclusionOur data suggest benefit of continuing CS until age 18 years and beyond on respiratory function including delayed need to start (continuous) NIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.